AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biotage

Transaction in Own Shares Jul 1, 2010

2894_rns_2010-07-01_f705e05e-d6fa-4085-957e-22a001c5f4c5.pdf

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

Press release Biotage AB

Contact: SE-753 18 Uppsala Torben Jörgensen, President and CEO Tel+46 18 56 59 00 Tel: +46 707 49 05 84, [email protected] www.biotage.com

Kungsgatan 76

Uppsala July 1, 2010

Biotage AB (publ) – disclosure notice of substantial holding of shares

Biotage AB (publ) has on 30 June 2010 bought back 56,000 shares. The Company`s aggregated holding of own shares thereby amounts to 4,441,987 shares, corresponding to 5.02 percent of the total amount of shares and votes in the Company.

The total amount of shares outstanding, including shares held in treasury, amounts to 88,486,320.

Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at CET 8.30 am on 1 July 2010.

About Biotage

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world's largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the US, UK and Japan. Biotage has 245 employees and had sales of 394.1 MSEK in 2009. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.